LUPIN LIMITED
Clinical Trials
32
Trial Phases
5 Phases
Drug Approvals
39
Drug Approvals
Clinical Trials
Distribution across different clinical trial phases (29 trials with phase data)• Click on a phase to view related trials
An Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Once Daily Mexiletine PR in Patients With Myotonic Dystrophy Type 1 and Type 2 Who Have Completed MEX-DM-302 Study.
- Conditions
- Myotonic Dystrophy
- Interventions
- First Posted Date
- 2024-08-12
- Last Posted Date
- 2024-08-12
- Lead Sponsor
- Lupin Ltd.
- Target Recruit Count
- 176
- Registration Number
- NCT06549400
The Efficacy and Safety of Once Daily Mexiletine PR in Patients With Myotonic Dystrophy Type 1 and Type 2
- Conditions
- Myotonic Dystrophy
- Interventions
- First Posted Date
- 2024-07-26
- Last Posted Date
- 2024-07-26
- Lead Sponsor
- Lupin Ltd.
- Target Recruit Count
- 176
- Registration Number
- NCT06523400
A Study of LNP3794 in Subjects With NRAS/KRAS Mutated Advanced or Metastatic Refractory Solid Tumors
- Conditions
- NRAS/KRAS Mutated Advanced or Metastatic Refractory Solid Tumors
- Interventions
- First Posted Date
- 2022-01-12
- Last Posted Date
- 2023-03-17
- Lead Sponsor
- Lupin Ltd.
- Target Recruit Count
- 15
- Registration Number
- NCT05187858
- Locations
- 🇧🇪
Cliniques universitaires Saint-Luc, Brussels, Belgium
🇳🇱Amsterdam UMC, Amsterdam, Netherlands
🇬🇧Sarah Cannon Research Institute, London, United Kingdom
Study to Investigate the Efficacy and Safety of Mexiletine in Patients With Myotonic Dystrophy Type 1 and Type 2
- Conditions
- Myotonic Dystrophy Type 1 and Type 2
- Interventions
- Drug: Placebo
- First Posted Date
- 2021-01-07
- Last Posted Date
- 2024-05-06
- Lead Sponsor
- Lupin Ltd.
- Registration Number
- NCT04700046
Study to Compare Efficacy and Safety of LUBT010 and Lucentis® in Patients With Neovascular AMD
- Conditions
- Neovascular Age-related Macular Degeneration
- Interventions
- Drug: LUBT010 (proposed ranibizumab biosimilar)
- First Posted Date
- 2020-12-30
- Last Posted Date
- 2024-08-07
- Lead Sponsor
- Lupin Ltd.
- Target Recruit Count
- 600
- Registration Number
- NCT04690556
- Locations
- 🇮🇳
The Eye Care Center, Guwahati, Assam, India
🇮🇳Rising Retina Clinic, Ahmedabad, Gujarat, India
🇮🇳Government Eye Hospital M & J Institute of Ophthalmology, Ahmedabad, Gujarat, India
- Prev
- 1
- 2
- 3
- Next
News
Lupin Secures $50 Million Licensing Deal with Zentiva for Global Certolizumab Pegol Biosimilar Rollout
Lupin has entered into a strategic licensing and supply agreement with Czech-based Zentiva to commercialize its biosimilar version of Certolizumab Pegol across multiple global markets.
Lupin Partners with Sino Universal Pharmaceuticals to Commercialize Tiotropium DPI for COPD Treatment in China
Lupin has signed a license and supply agreement with Sino Universal Pharmaceuticals for the commercialization of tiotropium dry powder inhaler (18 mcg/capsule) in China for chronic obstructive pulmonary disease treatment.
Harmony Biosciences Secures Patent Protection for WAKIX Through 2030 Settlement with Lupin
Harmony Biosciences reached a settlement agreement with Lupin Limited that prevents generic competition for WAKIX until January 2030, strengthening the company's intellectual property position for its narcolepsy treatment.
US Court Allows Lupin and Zydus to Expand Patent Defense Arguments in Myrbetriq Generic Drug Case
A US court has permitted Lupin Ltd. and Zydus Lifesciences Ltd. to expand their patent argument scope in their defense against Astellas Pharma's Myrbetriq patent litigation.
Lupin's PRMT5 Inhibitor LNP7457 Shows Promising Safety Profile in Phase 1 Solid Tumor Trial
Lupin Limited will present Phase 1a clinical trial data for LNP7457, a novel PRMT5 inhibitor, at ASCO 2025 in Chicago from May 30 to June 3.
Novartis Launches Zero-Interest Payment Plan for High-Cost Cholesterol Drug Inclisiran in India
Novartis has introduced a first-of-its-kind financing scheme with Pine Labs for its cholesterol-lowering drug Sybrava (inclisiran) in India, offering zero-interest EMI options to improve patient access.
Lupin Partners with SteinCares to Commercialize Ranibizumab Biosimilar Across Latin America
Lupin Limited has signed a license and supply agreement with SteinCares for the commercialization of its biosimilar ranibizumab across Latin American markets, excluding Mexico and Argentina.
Lupin Receives FDA Approval for Generic Rivaroxaban Tablets for Thrombosis Prevention
Lupin has received U.S. FDA approval for its generic version of Rivaroxaban Tablets, expanding its cardiovascular portfolio with a key anticoagulant medication.
NPPA Sets Retail Prices for 84 Drugs Including Empagliflozin Combinations Following Patent Expiry
India's National Pharmaceutical Pricing Authority (NPPA) has fixed retail prices for 84 new drug formulations, including 36 combinations containing the recently off-patent diabetes medication empagliflozin.
Pretomanid Price Drops 25%, Boosting Access to Life-Saving TB Treatment Across Africa
The price of pretomanid, a critical component of drug-resistant tuberculosis treatment, has fallen to $169 per course, down from $364 in 2019, making it available for less than $1 per day.